Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.

Abstract

The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. A double-blind 12-week evaluation suggested comparable efficacy between 1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 equally divided doses. A lower incidence of side effects was noted in the oxaprozin group. An open 6-month study substantiated the efficacy and safety of oxaprozin.

• Authors: W J Reynolds, S F Shaar, A Buik, W J Lancee
• Journal: The Journal of rheumatology (J Rheumatol) 1979 May-Jun Vol. 6 Issue 3 Pg. 345-50 ISSN: 0315-162X [Print] Canada
• PMID: 385873 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Oxazoles
• Propionates
• Aspirin

Topics

• Arthritis, Rheumatoid (drug therapy)
• Aspirin (administration & dosage, therapeutic use)
• Chemical Phenomena
• Chemistry
• Clinical Trials as Topic
• Double-Blind Method
• Drug Evaluation
• Humans
• Oxazoles (administration & dosage, therapeutic use)
• Propionates (administration & dosage, therapeutic use)